Andelyn Biosciences

Reliably Expert. Purposely Driven.

Andelyn Biosciences

Beginning operations in late 2020, Andelyn Biosciences will become a Phase 3 compliant Good Manufacturing Practices (cGMP) clinical manufacturing facility producing materials for phase 1, 2, and 3 gene therapy clinical studies for biotechnology and pharmaceutical industries around the world.

Andelyn Biosciences is driven by its purpose, its reliable quality and its expertise. In short, the company is a game-changer. Unique scientific and manufacturing capabilities are paired with life-changing research. Therapies for incurable diseases and rare disorders are the result.

Andelyn Biosciences’ unique business model leads to reinvestment into pioneering research conducted at the Abigail Wexner Research Institute at Nationwide Children's, from basic discovery science to population health research on a broad range of challenges affecting children’s health.

Want to stay informed about Andelyn Biosciences?

Receive company updates by sending your name, company and email address to: AndelynInfo@NationwideChildrens.org.

Established as an affiliate company of Nationwide Children’s Hospital and its Research Institute, Andelyn Biosciences is a product of Nationwide Children’s Hospital’s success in clinical manufacturing and gene therapy. Nationwide Children’s Hospital is investing in Andelyn Biosciences to support Phase III studies for clinical manufacturing with these capabilities scheduled to begin in the third quarter of 2020. Andelyn Biosciences is targeting 2023 for the completion of a state of the art, GMP, manufacturing facility capable of early stage development through commercial scale manufacturing.

Email Us